摘要
目的探讨复方鳖甲软肝片与恩替卡韦联合治疗乙肝肝硬化的临床效果。方法收集2014年1月~2016年1月期间来我院治疗的乙肝肝硬化患者共150例作为研究对象,随机分组,观察组和对照组各75例,对照组口服恩替卡韦治疗,0.5 mg/次,1次/d;观察组在对照组基础上口服复方鳖甲软肝片治疗,4片/次,3次/d,治疗1年后比较治疗前后肝功能、HBV-DNA、肝纤维化指标。结果 (1)肝功能:治疗后两组ALT、AST、TBIL与治疗前比较明显降低,观察组明显低于对照组,差异有统计学意义(P<0.05)。(2)HBV-DNA:治疗后两组HBV-DNA与治疗前比较明显下降,观察组HBV-DNA明显低于对照组,差异有统计学意义(P<0.05)。(3)肝纤维化指标:治疗后两组HA、Ⅳ-C、LN、PC-Ⅲ与治疗前比较明显降低,观察组水平明显低于对照组,差异有统计学意义(P<0.05)。结论复方鳖甲软肝片与恩替卡韦联合用于乙肝肝硬化的治疗中效果显著,可明显改善患者的肝功能,控制HBV-DNA复制,降低肝纤维化状态,建议临床推广应用。
Objective To investigate the clinical effect of compound Biejia Ruangan tablet combined with entecavir in the treatment of hepatitis B liver cirrhosis. Methods A total of 150 patients with hepatitis B liver cirrhosis treated in our hospital from January 2014 to January 2016 were randomly divided into observation group （n=75） and control group （n=75）. The control group received oral administration of entecavir, 0.5 mg/time,1 time/d.The observation group was treated oral compound Biejia Ruangan tablet treatment, 4/ time, 3 times/d on the basis of treatment in the control group. After 1 year of treatment, liver function, HBV-DNA and liver fibrosis indexes were compared before and after treatment. Results （1）Liver function： ALT, AST and TBIL after treatment were significantly lower than those before treatment in the two groups, and ALT, AST and TBIL of the observation group were significantly lower than those of the control group, with statistically significant difference（P〈0.05）. （2）HBV-DNA： HBV-DNA after treatment was significantly lower than that before treatment in the two groups, and HBV-DNA in the observation group was significantly lower than that in the control group, with statistically significant difference（P〈0.05）. （3） Liver fibrosis indexes： HA, Ⅳ-C, LN, PC- Ⅲ after treatment were significantly lower than those before treatment in the two groups, and the liver fibrosis indexes in the observation group were significantly lower than those in the control group, with statistically significant difference （P〈0.05）. Conclusion Compound Biejia Ruangan tablet combined with entecavir in the treatment of hepatitis B cirrhosis has significant effect, whieh can obviously improve the liver function and control HBV-DNA replication,and can reduce the status of hepatic fibrosis.h is recommend for clinical application.
出处
《中国现代医生》
2017年第9期118-120,共3页
China Modern Doctor
关键词
乙肝肝纤维化
恩替卡韦
复方鳖甲软肝片
肝纤维化
Hepatitis B liver fibrosis
Entecavir
Compound Biejia Ruangan tablets
Hepatic fibrosis
